ORMD-0801
Type 2 Diabetes
Key Facts
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a clinical-stage biotech company with a mission to transform injectable therapies into oral medications, thereby improving patient compliance and quality of life. Its core achievement is the development of the POD™ (Protein Oral Delivery) technology platform, which is designed to protect and enhance the absorption of large molecules through the gastrointestinal tract. The company's strategy is centered on advancing its late-stage oral insulin candidate for Type 2 Diabetes and Non-Alcoholic Steatohepatitis (NASH), while exploring applications for other high-value peptides like GLP-1. Oramed has also demonstrated financial acumen through strategic transactions, generating significant non-dilutive returns for shareholders.
View full company profileAbout Oramed Pharmaceuticals
Oramed Pharmaceuticals is a clinical-stage biotech company with a mission to transform injectable therapies into oral medications, thereby improving patient compliance and quality of life. Its core achievement is the development of the POD™ (Protein Oral Delivery) technology platform, which is designed to protect and enhance the absorption of large molecules through the gastrointestinal tract. The company's strategy is centered on advancing its late-stage oral insulin candidate for Type 2 Diabetes and Non-Alcoholic Steatohepatitis (NASH), while exploring applications for other high-value peptides like GLP-1. Oramed has also demonstrated financial acumen through strategic transactions, generating significant non-dilutive returns for shareholders.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |